TLB Talbots (The)

TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced the appointment of Raymond Kong to its senior management team as Vice President of Sales.

Mr. Kong succeeds Duane Morrison, who will shift his focus to major accounts and doctor networks in the newly created position of Vice President of Business Development.

Mr. Kong has an accomplished history of sales, marketing and general management success within the global ophthalmic industry. Most recently, he served as General Manager for Alcon Laboratories Inc.'s ("Alcon") Indonesia business, where he had overall P&L responsibility for its surgical, pharmaceutical and consumer business segments. His 14 years of progressive experience at Alcon included previous positions involving sales and marketing management responsibility for Alcon's surgical/instrumentation business in global markets. Before joining Alcon, Mr. Kong enjoyed a 10-year career at Bausch & Lomb with a track record of performance and promotions to positions of increasing scale and responsibilities.

"I am really excited about the opportunity to bring someone with Raymond's experience onto our leadership team," commented TearLab's President & COO, Seph Jensen. "He brings a wealth of directly related sales leadership experience in our market and is uniquely positioned to help us achieve the growth opportunity ahead of us."

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
         (647) 872-4849
         skilmer@tearlab.com